100
NPS Score
VS
Karyopharm Therapeutics Claimed Company
- This companyis accepting feedback from verified employeesEMPLOYEE
PARTICIPANTS - 90
- TOTAL
RATINGS
Takeda
- EMPLOYEE
PARTICIPANTS - 258
- TOTAL
RATINGS
Karyopharm Therapeutics vs Takeda
Compare Karyopharm Therapeutics versus Takeda for CEO Rating, Overall Culture Score, Brand Ranking, and other ratings. Results were generated by 90 employees and customers of Karyopharm Therapeutics and 258 employees and customers of Takeda.
Karyopharm Therapeutics
Karyopharm Therapeutics's brand is ranked #- in the list of Global Top 1000 Brands, as rated by customers of Karyopharm Therapeutics. Their current market cap is $753.30M.
Takeda
Takeda's brand is ranked #- in the list of Global Top 1000 Brands, as rated by customers of Takeda.
5/5
Product Quality
4/5
5/5
Pricing
3.9/5
5/5
Customer Service
4/5
| 100% | Promoters |
|---|---|
| 0% | Passive |
| 0% | Detractors |
Net Promoter Score
Winner by 75
25
NPS Score
| 53% | Promoters |
|---|---|
| 19% | Passive |
| 28% | Detractors |
See how Karyopharm Therapeutics compares to its competitors
See how Takeda compares to its competitors
Working at Karyopharm Therapeutics vs Working at Takeda
82 / 100
CEO Rating
Winner by 5%
77 / 100
CEO Rating
Karyopharm Therapeutics
Karyopharm Therapeutics doesn't have enough ratings to calculate the Team Culture Ratings.
Know someone that works there? Invite them to rate their experience.
Takeda
Employees at Takeda rate their CEO, Christophe Weber, 77/100. This score is 5% lower than the scores of Karyopharm Therapeutics' CEO, Richard Paulson. Employees in the Engineering department rate Christophe Weber the highest.